Hongming Chen
President at METiS Therapeutics, Inc.
Profile
Hongming Chen is the founder of KALA BIO, Inc. which was founded in 2010.
She held the position of Chief Scientific Officer.
Currently, she is a Member of the National Academy of Engineering and President & Head-Research & Development at METiS Therapeutics, Inc. which she joined in 2022.
In the past, she worked as Director-Formulation Development at TransForm Pharmaceuticals, Inc. from 2000 to 2010, Senior Process Engineer at Merck & Co., Inc. in 1997, and Scientist at AstraZeneca PLC from 1997 to 2000.
Dr. Chen received her graduate degree in 1995 and doctorate in 1996 from Massachusetts Institute of Technology and her undergraduate degree in 1992 from The University of Texas at Austin.
Hongming Chen active positions
Companies | Position | Start |
---|---|---|
National Academy of Engineering
National Academy of Engineering Miscellaneous Commercial ServicesCommercial Services Part of The National Academies of Science, the National Academy of Engineering operates as a professional membership organization. The private company is based in Washington. | Corporate Officer/Principal | - |
METiS Therapeutics, Inc.
METiS Therapeutics, Inc. BiotechnologyHealth Technology METiS Therapeutics, Inc. is a discovery technology and therapeutics company that aims to develop best-in-class drug assets across various therapeutic areas. The company is based in Cambridge, MA and has subsidiaries in the United States and China. Joining the team offers an exciting career in therapeutics for AI drug discovery. METiS Therapeutics was founded by Christopher Lai and Wenshou Wang, with Christopher Lai serving as the CEO since incorporation. | President | 2022-01-19 |
Former positions of Hongming Chen
Companies | Position | End |
---|---|---|
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 2009-12-31 |
ASTRAZENECA PLC | Corporate Officer/Principal | 1999-12-31 |
MERCK & CO., INC. | Corporate Officer/Principal | 1996-12-31 |
KALA BIO, INC. | Founder | - |
Training of Hongming Chen
Massachusetts Institute of Technology | Graduate Degree |
The University of Texas at Austin | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
ASTRAZENECA PLC | Health Technology |
KALA BIO, INC. | Health Technology |
Private companies | 3 |
---|---|
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | Health Technology |
National Academy of Engineering
National Academy of Engineering Miscellaneous Commercial ServicesCommercial Services Part of The National Academies of Science, the National Academy of Engineering operates as a professional membership organization. The private company is based in Washington. | Commercial Services |
METiS Therapeutics, Inc.
METiS Therapeutics, Inc. BiotechnologyHealth Technology METiS Therapeutics, Inc. is a discovery technology and therapeutics company that aims to develop best-in-class drug assets across various therapeutic areas. The company is based in Cambridge, MA and has subsidiaries in the United States and China. Joining the team offers an exciting career in therapeutics for AI drug discovery. METiS Therapeutics was founded by Christopher Lai and Wenshou Wang, with Christopher Lai serving as the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Hongming Chen